ID   5555-EKAREV-NLS
AC   CVCL_E9CK
RX   PubMed=25873177;
RX   PubMed=26414886;
CC   Characteristics: Carries the FRET biosensor EKARrEV-NLS, which consists of a donor fluorescent protein CFP, an ERK substrate peptide derived from Cdc25, an optimized linker, a FHA1 phosphate binding domain, an acceptor fluorescent protein YFP and a nuclear localization signal (PubMed=25873177).
CC   Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=25873177).
CC   Genetic integration: Method=PiggyBac transposition; Gene=FPbase; ZRLU4; CFP (Note=Cyan fluorescent protein derived from GFP).
CC   Genetic integration: Method=PiggyBac transposition; Gene=FPbase; 8DNLG; YFP (Note=EYFP, yellow fluorescent protein derived from GFP).
CC   Genetic integration: Method=Transgenic mouse; Gene=MGI; MGI:1352467; Esr1 (Note=Ligand binding domain; with p.Gly525Arg. Fused to Cre = CreERT2).
CC   Breed/subspecies: C57BL/6 BRAF+/LSL-BRAFV600E;Tyr::CreERT2+/o transgenic.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_E9CJ ! 5555
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=25873177; DOI=10.1016/j.ccell.2015.03.008; PMCID=PMC4402404;
RA   Hirata, Eishu
RA   Girotti, Maria Romina
RA   Viros, Amaya
RA   Hooper, Steven
RA   Spencer-Dene, Bradley
RA   Matsuda, Michiyuki
RA   Larkin, James
RA   Marais, Richard
RA   Sahai, Erik
RT   "Intravital imaging reveals how BRAF inhibition generates
RT   drug-tolerant microenvironments with high integrin beta1/FAK
RT   signaling.";
RL   Cancer Cell 27:574-588(2015).
//
RX   PubMed=26414886; DOI=10.1111/pcmr.12424; PMCID=PMC4737278;
RA   Seifert, Heike
RA   Hirata, Eishu
RA   Gore, Martin Eric
RA   Khabra, Komel
RA   Messiou, Christina
RA   Larkin, James
RA   Sahai, Erik
RT   "Extrinsic factors can mediate resistance to BRAF inhibition in
RT   central nervous system melanoma metastases.";
RL   Pigment Cell Melanoma Res. 29:92-100(2016).
//